Explore Accera. Discover progress.

Accera, Inc., is a privately held biotechnology company that develops therapies to treat central nervous system disorders. Our novel therapeutic approach, including a proprietary scientific platform, has led to breakthrough discoveries that positively impact patients and their families.

Axona®, a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s disease, is Accera’s first product to reach the market.

Learn more about how Axona may help people with mild to moderate Alzheimer’s at

Nourish Logo (High Rez)

References: 1. Henderson ST, Vogel JL, Barr LJ, et al. Study of the ketogenic agent AC-1202, in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009;6:31. 2. National Institute on Aging. Alzheimer’s disease [fact sheet]. Reprinted September 2012. Accessed November 20, 2013. 3. Cunnane S, Nugent S, Roy M, et al. Brain fuel metabolism, aging, and Alzheimer’s disease. Nutrition. 2011;27(1):3-20.